157.24

0.79% -1.26

Pre-market: 155.92 -1.32 -0.84%

Astrazeneca Plc (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca Plc stock is traded at $157.24, with a volume of 3.60M. It is down -0.79% in the last 24 hours and down -7.22% over the past month. A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Previous Close:

$158.50

Open:

$157.85

24h Volume:

3.60M

Relative Volume:

1.31

Market Cap:

$243.86B

Revenue:

$60.48B

Net Income/Loss:

$10.40B

P/E Ratio:

47.22

EPS:

3.3297

Net Cash Flow:

$8.05B

1W Performance:

-2.38%

1M Performance:

-7.22%

6M Performance:

-23.50%

1Y Performance:

+101.74%

1-Day Range:

$156.97

$158.44

1-Week Range:

$156.97

$162.72

52-Week Range:

$72.89

$212.71

Astrazeneca Plc Stock (AZN) Company Profile

Name

Astrazeneca Plc

Sector

Healthcare (1075)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

96,100

Twitter

@AstraZeneca

Next Earnings Date

2026-07-27

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN vs LLY, JNJ, ABBV, MRK, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca Plc	157.24	245.82B	60.48B	10.40B	8.05B	3.3297
LLY Lilly Eli Co	1,209.00	1.09T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	262.08	628.65B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	250.82	439.59B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	135.55	327.94B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	151.72	289.52B	54.66B	13.58B	16.05B	7.0171

Astrazeneca Plc Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-27-26	Initiated	Citigroup	Buy
Oct-27-25	Resumed	Jefferies	Buy
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca Plc Stock (AZN) Latest News

01:04 AM

AstraZeneca stock holds near $157 after earnings beat - AD HOC NEWS

01:04 AM

Aug 13, 2026

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? - The Motley Fool

Aug 13, 2026

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story? - Yahoo Finance

Aug 13, 2026

Sarah Ketterer's Top Q2 2026 Move: AstraZeneca PLC at a 3.92% Po - GuruFocus

Aug 13, 2026

AstraZeneca stock holds steady as Q2 2026 earnings beat supports outlook - AD HOC NEWS

Aug 13, 2026

Wealthcare Advisory Partners LLC Purchases Shares of 12,112 Astrazeneca Plc $AZN - MarketBeat

Aug 13, 2026

AstraZeneca (LSE:AZN) Leads a Defensive Test for UK Blue Chips - Kalkine Media

Aug 13, 2026

Aug 12, 2026

AstraZeneca slips Wednesday, underperforms market - MarketWatch

Aug 12, 2026

AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Combo Gets Approval in China - marketscreener.com

Aug 12, 2026

Daiichi, AstraZeneca drug Enhertu wins further approval in China - marketscreener.com

Aug 12, 2026

AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Shift Blue-Chip Attention To Drug Pipelines - Kalkine Media

Aug 12, 2026

AstraZeneca (LSE:AZN) Puts Innovation At The Centre Of Blue-Chip Healthcare - Kalkine Media

Aug 12, 2026

How AstraZeneca’s $400bn deal unravelled - Financial Times

Aug 12, 2026

Aug 11, 2026

AstraZeneca PLC (Dinari Tokenized Stock) (AZN) Price Prediction for 2026 to 2031 - Bybit

Aug 11, 2026

AstraZeneca and Bristol-Myers Squibb's $401.9 Billion Merger Collapses in Abrupt Boardroom Reversal - finance.biggo.com

Aug 11, 2026